74D Stock Overview A specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
HLS Therapeutics Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for HLS Therapeutics Historical stock prices Current Share Price CA$2.56 52 Week High CA$3.42 52 Week Low CA$1.95 Beta 1.07 1 Month Change 9.40% 3 Month Change 5.79% 1 Year Change -3.76% 3 Year Change -74.01% 5 Year Change n/a Change since IPO -76.10%
Recent News & Updates
Third quarter 2024 earnings released: US$0.15 loss per share (vs US$0.21 loss in 3Q 2023) Nov 08 HLS Therapeutics Inc. Updates Earnings Guidance for the Year 2024
HLS Therapeutics Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.29 loss in 2Q 2023) Aug 09 HLS Therapeutics Inc. Reiterates Earnings Guidance for the Full Year 2024
HLS Therapeutics Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 25 See more updates
Third quarter 2024 earnings released: US$0.15 loss per share (vs US$0.21 loss in 3Q 2023) Nov 08 HLS Therapeutics Inc. Updates Earnings Guidance for the Year 2024
HLS Therapeutics Inc. to Report Q3, 2024 Results on Nov 07, 2024 Oct 24
Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.29 loss in 2Q 2023) Aug 09 HLS Therapeutics Inc. Reiterates Earnings Guidance for the Full Year 2024
HLS Therapeutics Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 25
HLS Therapeutics Inc. Announces New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment May 29
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024 May 12
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024 May 11
Now 30% undervalued after recent price drop May 11
First quarter 2024 earnings released: US$0.19 loss per share (vs US$0.18 loss in 1Q 2023) May 10
HLS Therapeutics Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 27
New minor risk - Share price stability Apr 09
HLS Therapeutics Inc., Annual General Meeting, Jun 07, 2024 Apr 09
No longer forecast to breakeven Mar 17 HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024 Mar 15
Full year 2023 earnings released: US$0.85 loss per share (vs US$0.73 loss in FY 2022) Mar 14
HLS Therapeutics Inc. to Report Q4, 2023 Results on Mar 14, 2024 Mar 01
Forecast to breakeven in 2026 Dec 31 HLS Therapeutics Inc. Announces CFO Changes Dec 18
HLS Therapeutics Inc. Announces Results from New REDUCE-IT Analyses Nov 15
New minor risk - Market cap size Nov 12
Third quarter 2023 earnings released: US$0.21 loss per share (vs US$0.14 loss in 3Q 2022) Nov 10
HLS Therapeutics Inc. to Report Q3, 2023 Results on Nov 09, 2023 Oct 27
Forecast to breakeven in 2025 Aug 13
Second quarter 2023 earnings released: US$0.29 loss per share (vs US$0.28 loss in 2Q 2022) Aug 11 HLS Therapeutics Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
High number of new directors Jul 02
HLS Therapeutics Inc. Announces Board Changes Jun 23
HLS Therapeutics Inc. Elects Christian Roy as Director Jun 17
Independent Director recently bought €290k worth of stock Jun 14
New major risk - Share price stability Jun 13
Hls Therapeutics Inc. Announces Resignation of Director Jun 09
First quarter 2023 earnings released: US$0.18 loss per share (vs US$0.11 loss in 1Q 2022) May 12
HLS Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023 May 04
Upcoming dividend of CA$0.05 per share at 3.3% yield Apr 20
Full year 2022 earnings released: US$0.73 loss per share (vs US$0.41 loss in FY 2021) Mar 17
Upcoming dividend of CA$0.05 per share Jan 23
HLS Therapeutics Inc. Appoints Kyle Dempsey as Independent Director Nov 30
Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.061 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.061 loss in 3Q 2021) Nov 11
HLS Therapeutics Inc. Declares a Dividend, Payable on March 15, 2023 Nov 11
HLS Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022 Oct 28
Upcoming dividend of CA$0.05 per share Oct 21
Co-Founder & Chairman recently sold €1.6m worth of stock Sep 03
Forecast breakeven date pushed back to 2024 Aug 26
Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.069 loss in 2Q 2021) Aug 12
HLS Therapeutics Inc. Declares Dividend, Payable on December 15, 2022 Aug 12
HLS Therapeutics Inc. to Report Q2, 2022 Results on Aug 11, 2022 Jul 29
HLS Therapeutics Inc. Enters into a Product Listing Agreement with Ontario Jul 26
Upcoming dividend of CA$0.05 per share Jul 21
HLS Therapeutics Inc. Obtains Public Reimbursement for Vascepa® in New Brunswick and with Other Public Payors Jun 23 HLS Therapeutics Inc. Announces Board Changes HLS Therapeutics Inc. Announces Board Changes
Co-Founder & Executive Chairman recently sold €461k worth of stock May 15
HLS Therapeutics Inc. Declares Dividend, Payable on September 15, 2022 May 08
First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.15 loss in 1Q 2021) May 06
Forecast breakeven date pushed back to 2023 Apr 27
Upcoming dividend of CA$0.05 per share Apr 21
HLS Therapeutics Inc., Annual General Meeting, Jun 17, 2022 Apr 15
Forecast breakeven date pushed back to 2023 Mar 19
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 18
Upcoming dividend of CA$0.05 per share Jan 20
Co-Founder & Executive Chairman recently sold €314k worth of stock Dec 10
Third quarter 2021 earnings released: US$0.061 loss per share (vs US$0.055 loss in 3Q 2020) Nov 09
Upcoming dividend of CA$0.05 per share Oct 21
Forecast to breakeven in 2022 Sep 23
Co-Founder & Director recently sold €1.2m worth of stock Sep 02
Co-Founder & Executive Chairman recently sold €116k worth of stock Aug 21
Second quarter 2021 earnings released: US$0.07 loss per share (vs US$0.20 loss in 2Q 2020) Aug 06
Upcoming dividend of CA$0.05 per share Jul 22
Chief Financial Officer recently bought €52k worth of stock May 23
First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.005 profit in 1Q 2020) May 08
HLS Therapeutics Inc. Declares Dividend, Payable on September 15, 2021 May 07
Upcoming dividend of CA$0.05 per share Apr 22
Co-Founder & Director recently sold €675k worth of stock Apr 04
HLS Therapeutics Inc. Declares Dividend, Payable on June 15, 2021 Mar 19
Full year 2020 earnings released: US$0.48 loss per share (vs US$0.67 loss in FY 2019) Mar 19
HLS Therapeutics Announces VASCEPA® Found in Prespecified and Post Hoc Analyses, REDUCE-IT® Study Presented at International Stroke Conference 2021 Mar 18
HLS Therapeutics Inc. to Report Q4, 2020 Results on Mar 18, 2021 Mar 05
New 90-day high: €11.70 Feb 20
HLS Therapeutics Inc. Announces New Support from Independent Medical Societies for the Use of Vascepa Jan 29
Co-Founder & Director recently sold €760k worth of stock Dec 25
HLS Therapeutics Inc. Announces Update on Health Canada Filings for MyCare and Trinomia Dec 18
HLS Therapeutics Reports Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with Vascepa® (Icosapent Ethyl) Dec 15
Co-Founder & Director recently sold €2.2m worth of stock Nov 27 Shareholder Returns 74D DE Pharmaceuticals DE Market 7D 2.4% 2.2% 0.7% 1Y -3.8% -16.8% 8.4%
See full shareholder returns
Return vs Market: 74D underperformed the German Market which returned 8.4% over the past year.
Price Volatility Is 74D's price volatile compared to industry and market? 74D volatility 74D Average Weekly Movement 7.9% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 12.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 74D's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 74D's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels.
Show more HLS Therapeutics Inc. Fundamentals Summary How do HLS Therapeutics's earnings and revenue compare to its market cap? 74D fundamental statistics Market cap €84.54m Earnings (TTM ) -€21.47m Revenue (TTM ) €55.48m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 74D income statement (TTM ) Revenue US$56.94m Cost of Revenue US$14.36m Gross Profit US$42.59m Other Expenses US$64.62m Earnings -US$22.03m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.69 Gross Margin 74.79% Net Profit Margin -38.70% Debt/Equity Ratio 85.4%
How did 74D perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 06:23 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources HLS Therapeutics Inc. is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Martin Bloom Burton & Co. Tania Armstrong-Whitworth Canaccord Genuity George Ulybyshev Clarus Securities Inc.
Show 5 more analysts 